Background Background The optimal
The optimal pharmacological treatment of unipolar pharmacological treatment of unipolar psychotic depression is uncertain. psychotic depression is uncertain.
Aims Aims To compare the clinical
To compare the clinical effectiveness of pharmacological effectiveness of pharmacological treatments for patients with unipolar treatments for patients with unipolar psychotic depression. psychotic depression.
Method
Method Systematic review and meta-Systematic review and metaanalysis of randomised controlled trials. analysis of randomised controlled trials.
Results
Results Ten trials were included in the Ten trials were included in the review.We found no evidence thatthe review.We found no evidence thatthe combination of an antidepressant with an combination of an antidepressant with an antipsychotic is more effective than an antipsychotic is more effective than an antidepressant alone.This combination antidepressant alone.This combination was statistically more effective than an was statistically more effective than an antipsychotic alone. antipsychotic alone.
Conclusions
Conclusions Antidepressant mono-Antidepressant monotherapy and adding an antipsychotic if the therapy and adding an antipsychotic if the patient does not respond, or starting with patient does not respond, or starting with the combination of an antidepressant and the combination of an antidepressant and an antipsychotic, both appear to be an antipsychotic, both appear to be appropriate options for patients with appropriate options for patients with unipolar psychotic depression.However, unipolar psychotic depression.However, clinically the balance between risks and clinically the balance between risks and benefits may suggestthe first option benefits may suggestthe first option should be preferred for many patients. should be preferred for many patients. Starting with an antipsychotic alone Starting with an antipsychotic alone appears to be inadequate. appears to be inadequate.
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For unipolar psychotic depression, in which For unipolar psychotic depression, in which psychotic features appear in the context of psychotic features appear in the context of a major depressive episode, electrocon-a major depressive episode, electroconvulsive therapy (ECT) is considered by vulsive therapy (ECT) is considered by many clinicians to be the most effective many clinicians to be the most effective and therefore the first-line treatment. and therefore the first-line treatment. Pharmacotherapy is also often considered Pharmacotherapy is also often considered a suitable first-line treatment, because a suitable first-line treatment, because many patients prefer drug therapy to ECT many patients prefer drug therapy to ECT and moreover, after a successful course of and moreover, after a successful course of ECT subsequent treatment with medication ECT subsequent treatment with medication is often needed to prevent relapse. If the is often needed to prevent relapse. If the choice is pharmacotherapy, it is unclear choice is pharmacotherapy, it is unclear whether one can start with an antidepres-whether one can start with an antidepressant alone or should combine it with an sant alone or should combine it with an antipsychotic. Some reviews suggest that antipsychotic. Some reviews suggest that one may consider antidepressant mono-one may consider antidepressant monotherapy before adding an antipsychotic therapy before adding an antipsychotic (Nelson & McElroy, 1997; Wheeler-Vega (Nelson & McElroy, 1997; Wheeler-Vega et al et al, 2000) . However, recent US and Brit-, 2000) . However, recent US and British guidelines recommend the combination ish guidelines recommend the combination (American Psychiatric Association, 2000; (American Psychiatric Association, 2000;  National Institute for Clinical Excellence, National Institute for Clinical Excellence, 2004) . We report a systematic review of 2004). We report a systematic review of the evidence regarding the pharmacological the evidence regarding the pharmacological treatment of unipolar psychotic depression. treatment of unipolar psychotic depression. 
METHOD METHOD

Included studies Included studies
We included randomised controlled trials We included randomised controlled trials (RCTs) of the pharmacological treatment (RCTs) of the pharmacological treatment of patients with psychotic depression, pub-of patients with psychotic depression, published in any language. We expected to lished in any language. We expected to identify very few RCTs with the treatment identify very few RCTs with the treatment of psychotic depression as the primary of psychotic depression as the primary focus. We therefore also selected RCTs focus. We therefore also selected RCTs including patients with major depression including patients with major depression with and without psychotic features, in with and without psychotic features, in which the effects in the subgroup of which the effects in the subgroup of patients with psychotic depression were patients with psychotic depression were reported separately. The inclusion criteria reported separately. The inclusion criteria for the review were as follows. for the review were as follows.
Participants Participants
We included RCTs investigating patients in We included RCTs investigating patients in any setting (in-patient and out-patient) with any setting (in-patient and out-patient) with a unipolar major depressive disorder having a unipolar major depressive disorder having a current major depressive episode with a current major depressive episode with psychotic features. If a trial had studied psychotic features. If a trial had studied patients with depressive episodes in the patients with depressive episodes in the course of a bipolar disorder, it was only course of a bipolar disorder, it was only included if the results in the non-bipolar included if the results in the non-bipolar depression group were reported separately depression group were reported separately or if the percentage of patients with bipolar or if the percentage of patients with bipolar depression did not exceed 20% of the total depression did not exceed 20% of the total study population. study population.
Interventions Interventions
We and FEATURES FEATURES [All Fields]))) combined with a search strat-[All Fields]))) combined with a search strategy for RCTs. egy for RCTs.
In step 1 of the search process, all In step 1 of the search process, all abstracts of the identified publications were abstracts of the identified publications were screened independently by two authors screened independently by two authors (50% by both J.W. and J.L., 50% by both (50% by both J.W. and J.L., 50% by both F.B. and W.N.) and studies were selected F.B. and W.N.) and studies were selected if they met the following criteria: if they met the following criteria:
(a) (a) the study was a randomised controlled the study was a randomised controlled trial; trial; In case of any doubt or disagreement In case of any doubt or disagreement between the reviewers, the publication between the reviewers, the publication was included. Next, the full articles were was included. Next, the full articles were obtained for the selected abstracts. In step obtained for the selected abstracts. In step 2, a trained medical student screened the 2, a trained medical student screened the full articles to select all trials in which: (a) full articles to select all trials in which: (a) patients with psychotic depression were patients with psychotic depression were not excluded; and (b) results in the sub-not excluded; and (b) results in the subgroup of patients with psychotic depression group of patients with psychotic depression were reported separately. were reported separately.
In case of any doubt the publication In case of any doubt the publication was included. In order to check the reliabil-was included. In order to check the reliability of this procedure a random selection of ity of this procedure a random selection of 60 articles were also screened by J.W., 60 articles were also screened by J.W., which revealed no publication that had which revealed no publication that had not been selected by the medical student. not been selected by the medical student. In addition, reference lists of included In addition, reference lists of included publications, related reviews and abstract publications, related reviews and abstract books of recent congresses were searched books of recent congresses were searched and trials were identified through personal and trials were identified through personal communication. In step 3, two authors communication. In step 3, two authors (J.W. and F.B.) independently reviewed all (J.W. and F.B.) independently reviewed all identified publications according to the identified publications according to the inclusion criteria. Any disagreement was inclusion criteria. Any disagreement was resolved by consensus discussion with a resolved by consensus discussion with a third author (W.N.). third author (W.N.).
Quality assessment Quality assessment
Two reviewers (J.W. and J.L.) assessed the Two reviewers (J.W. and J.L.) assessed the methodological quality of the included trials, methodological quality of the included trials, according to the criteria of the Cochrane according to the criteria of the Cochrane Collaboration. These criteria focus on ran-Collaboration. These criteria focus on randomisation procedures (especially allocation domisation procedures (especially allocation concealment and randomisation); whether concealment and randomisation); whether the study was double-blind, single-blind or the study was double-blind, single-blind or open randomised; analysis (stratification open randomised; analysis (stratification prior to treatment or non-stratification of prior to treatment or non-stratification of patients with psychotic patients with psychotic v.
v. non-psychotic de-non-psychotic depression in the RCTs that did not have the pression in the RCTs that did not have the treatment of psychotic depression as their treatment of psychotic depression as their main focus); and other aspects, such as main focus); and other aspects, such as reporting of the number of patients leaving reporting of the number of patients leaving the trial and the reasons for the withdrawals. the trial and the reasons for the withdrawals.
Types of outcome measures Types of outcome measures
The primary efficacy outcome used in the The primary efficacy outcome used in the analysis was clinical response based on analysis was clinical response based on observer-rated symptom reduction, for observer-rated symptom reduction, for example a reduction of at least 50% on example a reduction of at least 50% on the Hamilton Rating Scale for Depression the Hamilton Rating Scale for Depression (HRSD) or any other observer-rated (HRSD) or any other observer-rated depression severity rating scale, or a change depression severity rating scale, or a change score on the Clinical Global Impression -score on the Clinical Global Impression -Change (CGI-C) of 'much improved' or Change (CGI-C) of 'much improved' or 'very much improved'. As secondary effi-'very much improved'. As secondary efficacy outcomes, we investigated remission cacy outcomes, we investigated remission as defined in the reports and based on the as defined in the reports and based on the HRSD or other observer-rated depression HRSD or other observer-rated depression severity scale or change in severity on severity scale or change in severity on Clinical Global Impression -Severity Clinical Global Impression -Severity (CGI-S); and quality of life. (CGI-S); and quality of life.
The primary harm outcome used in the The primary harm outcome used in the analysis was overall withdrawal rate during analysis was overall withdrawal rate during acute treatment as a proxy measure of overall acute treatment as a proxy measure of overall acceptability of treatment. We also analysed acceptability of treatment. We also analysed withdrawal rates resulting from adverse withdrawal rates resulting from adverse effects, all-cause mortality and suicide. effects, all-cause mortality and suicide.
Data extraction Data extraction
Data were extracted on participants' char-Data were extracted on participants' characteristics, diagnosis (diagnostic instru-acteristics, diagnosis (diagnostic instrument, classification), intervention details ment, classification), intervention details and outcome measures. Data were ex-and outcome measures. Data were extracted independently by two reviewers tracted independently by two reviewers (J.W. and J.L.). (J.W. and J.L.).
Data analysis Data analysis
Data were entered into RevMan 4.2 (http:// Data were entered into RevMan 4.2 (http:// www.cc-ims.net/RevMan). For binary effi-www.cc-ims.net/RevMan). For binary efficacy outcomes a relative risk (with 95% cacy outcomes a relative risk (with 95% confidence intervals) was calculated for confidence intervals) was calculated for each comparison. When necessary, we con-each comparison. When necessary, we converted response data from the trials into verted response data from the trials into intention-to-treat response data by using intention-to-treat response data by using the total number of randomised patients the total number of randomised patients per group who had started with treatment per group who had started with treatment as the denominator. as the denominator.
RESULTS
Description of the studies Description of the studies
From the search in the Cochrane Central From the search in the Cochrane Central Register of Controlled Trials we identified Register of Controlled Trials we identified 1782 publications. The searches in Medline 1782 publications. The searches in Medline and EMBASE resulted in 720 and 831 pub-and EMBASE resulted in 720 and 831 publications respectively. The first step of lications respectively. The first step of screening the abstracts of these publications screening the abstracts of these publications resulted in 789 publications (749 from the resulted in 789 publications (749 from the Cochrane register, 38 from Medline and Cochrane register, 38 from Medline and 11 from EMBASE). The second step of 11 from EMBASE). The second step of screening the full articles resulted in the screening the full articles resulted in the identification of 52 publications (47, 3 identification of 52 publications (47, 3 and 2 respectively). Hand-searching of and 2 respectively). Hand-searching of reference lists of relevant reviews resulted reference lists of relevant reviews resulted in one further publication (Bellini in one further publication (Bellini et al et al, , 1994) , whereas hand-searching of the 1994), whereas hand-searching of the included publications revealed no other included publications revealed no other publication. The third step of reviewing publication. The third step of reviewing these 53 publications resulted in seven these 53 publications resulted in seven included studies. Finally, we added two included studies. Finally, we added two other publications which we knew were other publications which we knew were then in press: one by Van den Broek then in press: one by Van (2004) , reporting two similar trials. Thus, nine publications with a total of ten RCTs nine publications with a total of ten RCTs were included (Table 1) . were included (Table 1) .
In seven of the ten studies the treatment In seven of the ten studies the treatment of psychotic depression was the primary of psychotic depression was the primary focus. From three studies we used data focus. From three studies we used data from the subgroup of patients with psycho-from the subgroup of patients with psychosis, which were reported separately (Spiker sis, which were reported separately (Spiker & Kupfer, 1988; Bruijn & Kupfer, 1988; Bruijn et al et al, 1996; Van , 1996 ; Van den Broek den Broek et al et al, 2004) . Five RCTs did not , 2004). Five RCTs did not include only patients with unipolar psy-include only patients with unipolar psychotic depression. In the study by Zanardi chotic depression. In the study by Zanardi et al et al (1996) it was possible to exclude the (1996) it was possible to exclude the data relating to participants with bipolar data relating to participants with bipolar disorder. The study by Anton & Burch disorder. The study by Anton & Burch (1990) reported 15.8% (6 out of 38) cases (1990) reported 15.8% (6 out of 38) cases of bipolar disorder, and it is unclear how of bipolar disorder, and it is unclear how many of the 8 participants who left the many of the 8 participants who left the study and whose data were excluded before study and whose data were excluded before analysis had bipolar disorder. To solve this analysis had bipolar disorder. To solve this problem we assumed a random withdrawal problem we assumed a random withdrawal rate. In Spiker rate. In Spiker et al et al (1985) 15.5% of the pa-(1985) 15.5% of the patients in the results had bipolar disorder. In tients in the results had bipolar disorder. In Bruijn Bruijn et al et al (1996) and Zanardi (1996) and Zanardi et al et al (2000) (2000) we were able to exclude the data for pa-we were able to exclude the data for patients with bipolar disorder with the help tients with bipolar disorder with the help of additional information from the authors. of additional information from the authors.
Outcome measures Outcome measures
It was not possible to transfer the authors' It was not possible to transfer the authors' defined response data into rates based on defined response data into rates based on one definition (e.g. 50% reduction of the one definition (e.g. 50% reduction of the HRSD score). In addition, several authors HRSD score). In addition, several authors used response definitions based on what is used response definitions based on what is often considered remission. In the absence often considered remission. In the absence of a better option, we decided to use only of a better option, we decided to use only response data as reported by the authors. response data as reported by the authors.
In eight of the ten studies we recalcu-In eight of the ten studies we recalculated the intention-to-treat response rates lated the intention-to-treat response rates using all randomised patients as the denomi-using all randomised patients as the denominator. We thus included many patients who nator. We thus included many patients who were excluded from analyses by the original were excluded from analyses by the original researchers: from the study of Anton & researchers: from the study of Anton & Burch (1990) , 8 patients who left the study Burch (1990) , 8 patients who left the study before receiving 2 full weeks of active before receiving 2 full weeks of active medication; 9 and 3 patients, respectively medication; 9 and 3 patients, respectively from the studies of Bruijn from the studies of Bruijn et al et al (1996) (2004) , who left the trial between baseline (2004), who left the trial between baseline and the first visit after start of treatment and the first visit after start of treatment at week 1; and finally 7 patients who left at week 1; and finally 7 patients who left the studies of Spiker the studies of Spiker et al et al (1985) and Spiker (1985) and Spiker & Kupfer (1988) . Extracting continuous & Kupfer (1988) . Extracting continuous data of observer-rated depression severity data of observer-rated depression severity scales for analysis was impossible because scales for analysis was impossible because we were not able to convert these data we were not able to convert these data according to an intention-to-treat analysis according to an intention-to-treat analysis (Spiker (Spiker et al et al, 1985; Spiker & Kupfer, , 1985; Spiker & Kupfer, 1988; Anton & Burch, 1990; Bruijn 1988; Anton & Burch, 1990; Bruijn et al et al, , 1996; Mulsant 1996; Mulsant et al et al, 2001; Rothschild , 2001; Rothschild et et al al, 2004; Van den Broek , 2004; Van den Broek et al et al, 2004), and , 2004) , and in the two studies by Zanardi in the two studies by Zanardi et al et al (1996, (1996, 2000) no continuous data were given. 2000) no continuous data were given. Other efficacy outcome measures (e.g. Other efficacy outcome measures (e.g. change in quality of life) could not be change in quality of life) could not be extracted from the trials. extracted from the trials.
Overall rates of withdrawal were avail-Overall rates of withdrawal were available for all studies. Rates of withdrawal able for all studies. Rates of withdrawal because of adverse effects were available because of adverse effects were available in four studies (Spiker in four studies (Spiker et al et al, 1985; Anton , 1985; Anton & Burch, 1990; Mulsant & Burch, 1990; Mulsant et al et al, 2001; Van , 2001 ; Van den Broek den Broek et al et al, 2004) ; in three other studies , 2004); in three other studies these data were not based on an intention-to-these data were not based on an intention-totreat analysis (two in Rothschild treat analysis (two in Rothschild et al et al, 2004; , 2004 ; one in Bruijn one in Bruijn et al et al, 1996) , were not available , 1996), were not available in one study (Spiker & Kupfer, 1988) and in one study (Spiker & Kupfer, 1988 ) and were the same as the overall withdrawal were the same as the overall withdrawal rates in two studies (Zanardi rates in two studies (Zanardi et al et al, 1996 (Zanardi et al et al, , , 1996 (Zanardi et al et al, , 2000 . Withdrawals specifically owing to 2000). Withdrawals specifically owing to death or suicide were not reported in any death or suicide were not reported in any of the studies. of the studies.
Efficacy analyses Efficacy analyses
Only one RCT compared an antidepressant Only one RCT compared an antidepressant with a placebo (Spiker & Kupfer, 1988) . In with a placebo (Spiker & Kupfer, 1988) . In this study amitriptyline was not statistically this study amitriptyline was not statistically significantly more effective than placebo significantly more effective than placebo (RR (RR¼8.40, 95% CI 0.50-142.27; 8.40, 95% CI 0.50-142.27; P P¼0.14). 0.14). In four studies two different antidepres-In four studies two different antidepressants were compared directly. In one study sants were compared directly. In one study (Bruijn (Bruijn et al et al, 1996 ), imipramine under , 1996 , imipramine under plasma level control was statistically plasma level control was statistically significantly more effective than mirtaza-significantly more effective than mirtazapine (RR pine (RR¼3.00, 95% CI 1.01-8.95;
3.00, 95% CI 1.01-8.95; P P¼0.05). In another (Van den Broek 0.05). In another (Van den Broek et et al al, 2004) , imipramine under plasma level , 2004), imipramine under plasma level control was statistically significantly more control was statistically significantly more effective than fluvoxamine (RR effective than fluvoxamine (RR¼2.10, 2.10, 95% CI 1.06-4.17; 95% CI 1.06-4.17; P P¼0.03). In the first 0.03). In the first study by Zanardi study by Zanardi et al et al (1996) , sertraline (1996) , sertraline was statistically significantly more effective was statistically significantly more effective than paroxetine (RR than paroxetine (RR¼3.37, 95% CI 3.37, 95% CI 1.19-9.57; 1.19-9.57; P P¼0.02); the second (Zanardi 0.02); the second (Zanardi et al et al, 2000) did not find a statistically sig-, 2000) did not find a statistically significant difference between fluvoxamine nificant difference between fluvoxamine and venlafaxine. and venlafaxine.
In two studies the tricyclic antidepressant In two studies the tricyclic antidepressant (TCA) imipramine given under plasma level (TCA) imipramine given under plasma level control was compared with an antidepres-control was compared with an antidepressant of another class (mirtazapine or fluvox-sant of another class (mirtazapine or fluvoxamine). After pooling these studies (Bruijn amine). After pooling these studies (Bruijn et al et al, 1996; Van den Broek , 1996 
imipramine was statistically significantly imipramine was statistically significantly superior to the non-TCA (RR superior to the non-TCA (RR¼2.36, 95% 2.36, 95% CI 1.32-4.23, CI 1.32-4.23, P P¼0.004) (Fig. 1) . 0.004) (Fig. 1) . In three RCTs selective serotonin re-In three RCTs selective serotonin reuptake inhibitors (SSRIs) were studied. uptake inhibitors (SSRIs) were studied. Response rates to these SSRIs varied from Response rates to these SSRIs varied from 21.4% (paroxetine in , 1996) there was a statistically significant difference between two cally significant difference between two SSRIs, favouring sertraline. Combining the SSRIs, favouring sertraline. Combining the studies with SSRIs led to a mean response studies with SSRIs led to a mean response rate to SSRIs of 51.5%. A pooled compar-rate to SSRIs of 51.5%. A pooled comparison of SSRIs with other antidepressants ison of SSRIs with other antidepressants was not possible. was not possible.
One study (Spiker One study (Spiker et al et al, 1985) compar-, 1985) comparing antidepressant monotherapy (amitrip-ing antidepressant monotherapy (amitriptyline) with antipsychotic monotherapy tyline) with antipsychotic monotherapy (perphenazine) did not find a statistically (perphenazine) did not find a statistically significant difference (RR significant difference (RR¼2.09, 95% CI 2.09, 95% CI 0.64-6.82; 0.64-6.82; P P¼0.22). 0.22). We found two studies comparing anti-We found two studies comparing antipsychotic monotherapy (olanzapine) with psychotic monotherapy (olanzapine) with placebo (Rothschild placebo (Rothschild et al et al, 2004) . Pooling , 2004) . Pooling these studies did not show a statistically these studies did not show a statistically significant difference (RR significant difference (RR¼1.13, 95% CI 1.13, 95% CI 0.74-1.73; 0.74-1.73; P P¼0.57). 0.57). In two studies the combination of an In two studies the combination of an antidepressant (nortriptyline or amitrip-antidepressant (nortriptyline or amitriptyline) and an antipsychotic (perphenazine) tyline) and an antipsychotic (perphenazine) was compared with antidepressant mono-was compared with antidepressant monotherapy (Spiker therapy (Spiker et al et al, 1985; Mulsant , 1985; Mulsant et al et al, , 2001) . Pooling these two studies did not 2001). Pooling these two studies did not show a statistically significant difference show a statistically significant difference between a TCA plus an antipsychotic and between a TCA plus an antipsychotic and a TCA alone (RR a TCA alone (RR¼1.44, 95% CI 0.86-1.44, 95% CI 0.86-2.41; 2.41; P P¼0.16) (Fig. 2) . 0.16) (Fig. 2) . In three studies the combination of an In three studies the combination of an antidepressant and an antipsychotic was antidepressant and an antipsychotic was compared with antipsychotic monotherapy. compared with antipsychotic monotherapy. In one of these studies (Spiker In one of these studies (Spiker et al et al, 1985) , 1985) the combination of amitriptyline plus the combination of amitriptyline plus perphenazine was statistically significantly perphenazine was statistically significantly superior to perphena superior to perphenazine alone (RR zine alone (RR¼3.61, 3.61, 95% CI 1.23-10.56; 95% CI 1.23-10.56; P P¼0.02). In the other 0.02). In the other two studies comparing the combination of two studies comparing the combination of olanzapine plus fluoxetine (Rothschild olanzapine plus fluoxetine (Rothschild et et al al, 2004) with olanzapine alone, pooling , 2004) with olanzapine alone, pooling resulted in a significant advantage for the resulted in a significant advantage for the combination over the antipsychotic alone combination over the antipsychotic alone (RR (RR¼1.64, 95% CI 1.10-2.44;
1.64, 95% CI 1.10-2.44; P P¼0.01) 0.01) and over placebo (RR and over placebo (RR¼1.86, 95% CI 1.86, 95% CI 1.23-2.82; 1.23-2.82; P P¼0.003). Pooling the data 0.003). Pooling the data from all three studies comparing the combi-from all three studies comparing the combination of an antidepressant plus an anti-nation of an antidepressant plus an antipsychotic with an antipsychotic alone psychotic with an antipsychotic alone showed a statistically significant difference showed a statistically significant difference favouring the combination (RR favouring the combination (RR¼1.92, 1.92, 95% CI 1.32-2.80; 95% CI 1.32-2.80; P P¼0.0007) (Fig. 3) . 0.0007) (Fig. 3) .
Other analyses Other analyses
The rates of withdrawal from the studies The rates of withdrawal from the studies varied from 9% to 41%. In the two multi-varied from 9% to 41%. In the two multicentre trials with olanzapine/fluoxetine centre trials with olanzapine/fluoxetine (Rothschild (Rothschild et al et al, 2004 ) the rate was 102 , 2004) the rate was 102 out of 249 (41%), and these authors re-out of 249 (41%), and these authors reported even higher non-completion rates ported even higher non-completion rates (com (completers: 110 out of 249 pleters: 110 out of 249¼44%, thus 44%, thus the non-the non-completion rate was 56%). There completion rate was 56%). There was no statistically significant difference was no statistically significant difference in the overall withdrawal rates between in the overall withdrawal rates between any of the treatments, either in the individ-any of the treatments, either in the individual studies or after pooling of studies. ual studies or after pooling of studies.
DISCUSSION DISCUSSION
Despite our extensive search of the litera-Despite our extensive search of the literature, we identified very few RCTs investi-ture, we identified very few RCTs investigating the pharmacological treatment of gating the pharmacological treatment of patients with a unipolar major depressive patients with a unipolar major depressive episode with psychotic features (psychotic episode with psychotic features (psychotic depression). In addition to seven trials in depression). In addition to seven trials in which the treatment of patients with psy-which the treatment of patients with psychotic depression was a major focus of the chotic depression was a major focus of the study, we were able to find three other study, we were able to find three other trials that reported on the effects in a sub-trials that reported on the effects in a subgroup of patients with psychotic depression group of patients with psychotic depression separately. The authors of two of these stu-separately. The authors of two of these studies of both psychotic and non-psychotic dies of both psychotic and non-psychotic depression provided us with additional in-depression provided us with additional information on the results in the subgroups formation on the results in the subgroups of patients with psychotic depression. of patients with psychotic depression. Because of the numbers involved, we were Because of the numbers involved, we were not able to approach the authors of all not able to approach the authors of all RCTs comprising depressed patients to RCTs comprising depressed patients to request similar information. However, if request similar information. However, if 4 13 4 13 data from other RCTs on the subgroup of data from other RCTs on the subgroup of people with psychotic depression are avail-people with psychotic depression are available, we invite the authors of these trials to able, we invite the authors of these trials to provide us with the relevant data, so that provide us with the relevant data, so that we may update this systematic review. we may update this systematic review.
Underinvestigation of Underinvestigation of unipolar psychotic depression unipolar psychotic depression
That we identified only ten RCTs in psy-That we identified only ten RCTs in psychotic depression illustrates that this most chotic depression illustrates that this most severe form of depression is seriously severe form of depression is seriously underinvestigated. One probable reason underinvestigated. One probable reason for this is that it is difficult to conduct for this is that it is difficult to conduct RCTs in patients with psychotic depression. RCTs in patients with psychotic depression. These patients not only have a psychotic These patients not only have a psychotic illness, but often also are very anxious or illness, but often also are very anxious or physically ill. In addition, they are often physically ill. In addition, they are often offered ECT directly because many clini-offered ECT directly because many clinicians assume that ECT is more effective cians assume that ECT is more effective than pharmacotherapy. Patients with psy-than pharmacotherapy. Patients with psychotic depressive illness may be unable to chotic depressive illness may be unable to give informed consent or may tend to with-give informed consent or may tend to withdraw from trials. Furthermore -until the draw from trials. Furthermore -until the recent trials by Rothschild recent trials by Rothschild et al et al (2004) -(2004)pharmaceutical companies were not inter-pharmaceutical companies were not interested in conducting trials in psychotic ested in conducting trials in psychotic depression because this subgroup of depres-depression because this subgroup of depression is not considered a separate indication sion is not considered a separate indication for treatment by the regulatory authorities for treatment by the regulatory authorities and therefore is commercially unattractive. and therefore is commercially unattractive.
Implications of the study Implications of the study
Despite the paucity of RCTs, a few clini-Despite the paucity of RCTs, a few clinically relevant conclusions can be drawn. cally relevant conclusions can be drawn. First, there is no evidence for the clinical First, there is no evidence for the clinical belief that an antidepressant alone is belief that an antidepressant alone is ineffective in psychotic depression. In seven ineffective in psychotic depression. In seven of the ten studies there was at least one of the ten studies there was at least one treatment arm with an antidepressant as treatment arm with an antidepressant as monotherapy, with in total 11 treatment monotherapy, with in total 11 treatment arms. In 5 of these treatment arms the anti-arms. In 5 of these treatment arms the antidepressant was effective in more than 50% depressant was effective in more than 50% of the patients: imipramine in Bruijn of the patients: imipramine in Bruijn et al et al (1996) and Van den Broek (1996) (2000) . In three studies there was even a . In three studies there was even a statistically significant difference between statistically significant difference between two antidepressants. In two of these studies two antidepressants. In two of these studies imipramine (under plasma level control) imipramine (under plasma level control) was more effective than fluvoxamine (Van was more effective than fluvoxamine (Van den Broek den Broek et al et al, 2004) and mirtazapine , 2004) and mirtazapine (Bruijn (Bruijn et al et al, 1996 ) respectively, suggesting , 1996 respectively, suggesting that a tricyclic antidepressant is to be pre-that a tricyclic antidepressant is to be preferred over a non-tricyclic drug in patients ferred over a non-tricyclic drug in patients with psychotic depression. This finding is with psychotic depression. This finding is in line with three studies among hospita-in line with three studies among hospitalised, depressed patients in which clomipra-lised, depressed patients in which clomipramine was found to be more effective than mine was found to be more effective than citalopram, paroxetine or moclobemide re-citalopram, paroxetine or moclobemide respectively (Danish University Antidepres-spectively (Danish University Antidepressant Group, 1986 Group, , 1990 Group, , 1993 . In these sant Group, 1986 Group, , 1990 Group, , 1993 . In these three studies patients with psychotic de-three studies patients with psychotic depression were also included; unfortunately, pression were also included; unfortunately, however, it is not possible to identify which however, it is not possible to identify which patients these were, as this information was patients these were, as this information was not systematically recorded. In the third not systematically recorded. In the third trial finding a difference between two anti-trial finding a difference between two antidepressants (Zanardi depressants (Zanardi et al et al, 1996 (Zanardi et al et al, ), more , 1996 , more patients responded to sertraline than to par-patients responded to sertraline than to paroxetine, probably related to more patients oxetine, probably related to more patients withdrawing from the paroxetine group. It withdrawing from the paroxetine group. It is difficult to draw a conclusion from this is difficult to draw a conclusion from this study, as in another study (Zanardi study, as in another study (Zanardi et al et al, , 2000) the same group found good response 2000) the same group found good response rates to another SSRI, fluvoxamine, as well rates to another SSRI, fluvoxamine, as well as to venlafaxine. as to venlafaxine.
Second, there is no evidence that the Second, there is no evidence that the combination of an antidepressant with an combination of an antidepressant with an antipsychotic is more effective than an antipsychotic is more effective than an antidepressant alone. Therefore, it can be antidepressant alone. Therefore, it can be concluded that the recommendation in the concluded that the recommendation in the US and British guidelines (American Psychi-US and British guidelines (American Psychiatric Association, 2000; National Institute atric Association, 2000; National Institute for Clinical Excellence, 2004 ) that in psy-for Clinical Excellence, 2004 ) that in psychotic depression the combination therapy chotic depression the combination therapy should be preferred over an antidepressant should be preferred over an antidepressant alone is not reliably evidence-based, if not alone is not reliably evidence-based, if not necessarily incorrect. Clinically, the balance necessarily incorrect. Clinically, the balance between risks and benefits may suggest that between risks and benefits may suggest that initial monotherapy with an antidepressant initial monotherapy with an antidepressant should be the preferred option for many should be the preferred option for many patients. patients.
Finally, there is evidence that the Finally, there is evidence that the combination of an antidepressant with an combination of an antidepressant with an antipsychotic is more effective than an antipsychotic is more effective than an antipsychotic alone. This was the major re-antipsychotic alone. This was the major result of the study comparing amitriptyline sult of the study comparing amitriptyline plus perphenazine plus perphenazine v.
v. perphenazine alone perphenazine alone (Spiker (Spiker et al et al, 1985) and was also found in , 1985) and was also found in one of the studies comparing fluoxetine one of the studies comparing fluoxetine plus olanzapine plus olanzapine v.
v. olanzapine alone olanzapine alone (Rothschild (Rothschild et al et al, 2004) . Moreover, it , 2004) . Moreover, it was confirmed in the pooled analysis of was confirmed in the pooled analysis of these studies. Therefore, it is concluded these studies. Therefore, it is concluded that treatment should not begin with that treatment should not begin with antipsychotic monotherapy. antipsychotic monotherapy.
Limitations of the study Limitations of the study
Our review has several limitations. First, Our review has several limitations. First, none of the studies with antidepressant none of the studies with antidepressant monotherapy had a sample size exceeding monotherapy had a sample size exceeding 25 patients per group. The only two relative 25 patients per group. The only two relative large studies were the studies sponsored by large studies were the studies sponsored by Eli Lilly (Rothschild Eli Lilly (Rothschild et al et al, 2004) with around , 2004) with around 50 patients per group (olanzapine 48 and 53 50 patients per group (olanzapine 48 and 53 patients, and placebo 51 and 49 patients re-patients, and placebo 51 and 49 patients respectively), but with fewer patients in the spectively), but with fewer patients in the group receiving olanzapine plus fluoxetine group receiving olanzapine plus fluoxetine (25 and 23 respectively). As with all systema-(25 and 23 respectively). As with all systematic reviews, publication bias is a potentially tic reviews, publication bias is a potentially serious source of error. There were too few serious source of error. There were too few studies -especially too few larger studies -studies -especially too few larger studiesto investigate further the possibility of pub-to investigate further the possibility of publication bias, and so it cannot be ruled out. lication bias, and so it cannot be ruled out. Additionally, the relative high proportion Additionally, the relative high proportion of these small studies (5 out of 10) report-of these small studies (5 out of 10) reporting a significant difference between two ing a significant difference between two treatments suggests publication bias. treatments suggests publication bias.
Second, we could only use one outcome Second, we could only use one outcome measure regarding efficacy: the response measure regarding efficacy: the response rates as defined by the authors. It was im-rates as defined by the authors. It was impossible to recalculate these response rates possible to recalculate these response rates into a standard rate based on one definition into a standard rate based on one definition (e.g. HRSD score), as many studies used (e.g. HRSD score), as many studies used different versions of the HRSD or actually different versions of the HRSD or actually reported only remission rates. As some of reported only remission rates. As some of these authors' response definitions may these authors' response definitions may 4 14 4 14 TCA monotherapy (study-defined outcome). TCA monotherapy (study-defined outcome). actually be considered remission, this might actually be considered remission, this might have had an influence on the results of our have had an influence on the results of our meta-analysis. meta-analysis. Finally, there was considerable clinical Finally, there was considerable clinical heterogeneity between the trials, illustrated heterogeneity between the trials, illustrated by substantial differences in response rates by substantial differences in response rates to antidepressant monotherapy between to antidepressant monotherapy between the European and the US studies. Two Ita-the European and the US studies. Two Italian studies (Zanardi lian studies (Zanardi et al et al, 1996 (Zanardi et al et al, , 2000 (Zanardi et al et al, ) re-, 1996 (Zanardi et al et al, , 2000 reported high response rates (above 50%) to ported high response rates (above 50%) to SSRIs (with the exception of paroxetine), SSRIs (with the exception of paroxetine), and in the Dutch studies (Bruijn and in the Dutch studies (Bruijn et al et al, , 1996; Van den Broek 1996; Van den Broek et al et al, 2004 ) the re-, 2004) the response rate was above 50% to imipramine sponse rate was above 50% to imipramine (but not to mirtazapine and fluvoxamine).
(but not to mirtazapine and fluvoxamine). In contrast, the US studies reported re-In contrast, the US studies reported response rates below 50% (Spiker sponse rates below 50% (Spiker et al et al, , 1985; Spiker & Kupfer, 1988; Mulsant 1985; Spiker & Kupfer, 1988; Mulsant et et al al, 2001) . One likely reason for this US-, 2001) . One likely reason for this US-European discrepancy is differences be-European discrepancy is differences between the study populations. Although all tween the study populations. Although all studies required that patients fulfilled diag-studies required that patients fulfilled diagnostic criteria according to a specified nostic criteria according to a specified diagnostic classification, the reliability of diagnostic classification, the reliability of diagnosis may have been limited in diagnosis may have been limited in some -if not most -of the trials. Only some -if not most -of the trials. Only four trials used a semi-structured interview four trials used a semi-structured interview (Spiker (Spiker et al et al, 1985; Bruijn , 1985; Bruijn et al et al, 1996; , 1996 , 2004) , and only one of these trials (Bruijn 2004) , and only one of these trials (Bruijn et al et al, 1996) reported the specific psychotic , 1996) reported the specific psychotic features for all patients. This leaves open features for all patients. This leaves open the possibility that the conclusion that in the possibility that the conclusion that in a particular patient (for instance) a feeling a particular patient (for instance) a feeling of guilt was actually a delusion was drawn of guilt was actually a delusion was drawn differently across the trials in this review. A differently across the trials in this review. A similar problem may have played a part in similar problem may have played a part in the judgement as to whether a patient had the judgement as to whether a patient had a psychotic depression in the course of a psychotic depression in the course of unipolar disorder or bipolar disorder. unipolar disorder or bipolar disorder. 
The pharmacological treatment of delusional depression. The pharmacological treatment of delusional depression. Starting with antipsychotic monotherapy is not an appropriate treatment strategy. strategy.
LIMITATIONS LIMITATIONS
& & Our conclusions are based on only a few, small randomised controlled trials, and
Our conclusions are based on only a few, small randomised controlled trials, and publication bias cannot be ruled out. publication bias cannot be ruled out.
& & We could only use the outcome measures defined by the authors.
We could only use the outcome measures defined by the authors.
& & There was considerable clinical heterogeneity between the trials. There was considerable clinical heterogeneity between the trials.
